vs

Side-by-side financial comparison of BuzzFeed, Inc. (BZFD) and Ginkgo Bioworks Holdings, Inc. (DNA). Click either name above to swap in a different company.

BuzzFeed, Inc. is the larger business by last-quarter revenue ($56.5M vs $33.4M, roughly 1.7× Ginkgo Bioworks Holdings, Inc.). On growth, BuzzFeed, Inc. posted the faster year-over-year revenue change (0.6% vs -23.8%). BuzzFeed, Inc. produced more free cash flow last quarter ($-12.0M vs $-47.7M). Over the past eight quarters, BuzzFeed, Inc.'s revenue compounded faster (23.6% CAGR vs -6.2%).

BuzzFeed, Inc. is an American Internet media, news, and entertainment company with a focus on digital media. Based in New York City, BuzzFeed was founded in 2006 by Jonah Peretti and John S. Johnson III to focus on tracking viral content. Kenneth Lerer, co-founder and chairman of The Huffington Post, started as a co-founder and investor in BuzzFeed and is now the executive chairman.

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

BZFD vs DNA — Head-to-Head

Bigger by revenue
BZFD
BZFD
1.7× larger
BZFD
$56.5M
$33.4M
DNA
Growing faster (revenue YoY)
BZFD
BZFD
+24.4% gap
BZFD
0.6%
-23.8%
DNA
More free cash flow
BZFD
BZFD
$35.7M more FCF
BZFD
$-12.0M
$-47.7M
DNA
Faster 2-yr revenue CAGR
BZFD
BZFD
Annualised
BZFD
23.6%
-6.2%
DNA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BZFD
BZFD
DNA
DNA
Revenue
$56.5M
$33.4M
Net Profit
$-26.8M
Gross Margin
Operating Margin
-43.7%
-211.9%
Net Margin
-47.4%
Revenue YoY
0.6%
-23.8%
Net Profit YoY
-186.4%
EPS (diluted)
$-0.72
$-1.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BZFD
BZFD
DNA
DNA
Q4 25
$56.5M
$33.4M
Q3 25
$46.3M
$38.8M
Q2 25
$46.4M
$49.6M
Q1 25
$36.0M
$48.3M
Q4 24
$56.2M
$43.8M
Q3 24
$55.6M
$89.0M
Q2 24
$41.1M
$56.2M
Q1 24
$37.0M
$37.9M
Net Profit
BZFD
BZFD
DNA
DNA
Q4 25
$-26.8M
Q3 25
$-7.4M
$-80.8M
Q2 25
$-10.8M
$-60.3M
Q1 25
$-12.7M
$-91.0M
Q4 24
$31.0M
Q3 24
$2.1M
$-56.4M
Q2 24
$-7.5M
$-217.2M
Q1 24
$-35.7M
$-165.9M
Operating Margin
BZFD
BZFD
DNA
DNA
Q4 25
-43.7%
-211.9%
Q3 25
-12.9%
-231.8%
Q2 25
-7.5%
-132.1%
Q1 25
-38.1%
-184.1%
Q4 24
7.0%
-236.3%
Q3 24
2.8%
-62.0%
Q2 24
-13.6%
-396.7%
Q1 24
-63.4%
-469.1%
Net Margin
BZFD
BZFD
DNA
DNA
Q4 25
-47.4%
Q3 25
-16.1%
-207.9%
Q2 25
-23.3%
-121.6%
Q1 25
-35.2%
-188.2%
Q4 24
55.2%
Q3 24
3.8%
-63.3%
Q2 24
-18.2%
-386.4%
Q1 24
-96.5%
-437.3%
EPS (diluted)
BZFD
BZFD
DNA
DNA
Q4 25
$-0.72
$-1.41
Q3 25
$-0.20
$-1.45
Q2 25
$-0.28
$-1.10
Q1 25
$-0.33
$-1.68
Q4 24
$0.86
$-1.91
Q3 24
$0.05
$-1.08
Q2 24
$-0.20
$-4.23
Q1 24
$-0.98
$-3.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BZFD
BZFD
DNA
DNA
Cash + ST InvestmentsLiquidity on hand
$8.5M
$422.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$49.4M
$508.6M
Total Assets
$188.1M
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BZFD
BZFD
DNA
DNA
Q4 25
$8.5M
$422.6M
Q3 25
$34.3M
$495.5M
Q2 25
$29.7M
$559.4M
Q1 25
$34.3M
$325.3M
Q4 24
$22.4M
$561.6M
Q3 24
$53.7M
$616.2M
Q2 24
$45.5M
$730.4M
Q1 24
$44.5M
$840.4M
Stockholders' Equity
BZFD
BZFD
DNA
DNA
Q4 25
$49.4M
$508.6M
Q3 25
$75.9M
$559.8M
Q2 25
$81.1M
$613.0M
Q1 25
$93.8M
$647.4M
Q4 24
$104.8M
$716.1M
Q3 24
$71.7M
$797.9M
Q2 24
$67.2M
$833.1M
Q1 24
$73.7M
$987.3M
Total Assets
BZFD
BZFD
DNA
DNA
Q4 25
$188.1M
$1.1B
Q3 25
$211.2M
$1.2B
Q2 25
$210.4M
$1.2B
Q1 25
$203.2M
$1.3B
Q4 24
$221.4M
$1.4B
Q3 24
$276.5M
$1.5B
Q2 24
$272.9M
$1.6B
Q1 24
$299.0M
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BZFD
BZFD
DNA
DNA
Operating Cash FlowLast quarter
$-11.7M
$-47.7M
Free Cash FlowOCF − Capex
$-12.0M
$-47.7M
FCF MarginFCF / Revenue
-21.2%
-142.8%
Capex IntensityCapex / Revenue
0.5%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-20.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BZFD
BZFD
DNA
DNA
Q4 25
$-11.7M
$-47.7M
Q3 25
$1.7M
$-31.6M
Q2 25
$-10.1M
$-40.3M
Q1 25
$1.3M
$-51.5M
Q4 24
$-4.6M
$-42.4M
Q3 24
$9.6M
$-103.5M
Q2 24
$-12.4M
$-84.4M
Q1 24
$-13.3M
$-89.3M
Free Cash Flow
BZFD
BZFD
DNA
DNA
Q4 25
$-12.0M
$-47.7M
Q3 25
$892.0K
Q2 25
$-10.5M
$-40.3M
Q1 25
$956.0K
$-59.1M
Q4 24
$-4.7M
$-56.1M
Q3 24
$9.3M
$-118.6M
Q2 24
$-12.5M
$-111.4M
Q1 24
$-13.4M
$-96.0M
FCF Margin
BZFD
BZFD
DNA
DNA
Q4 25
-21.2%
-142.8%
Q3 25
1.9%
Q2 25
-22.7%
-81.2%
Q1 25
2.7%
-122.4%
Q4 24
-8.4%
-128.0%
Q3 24
16.7%
-133.2%
Q2 24
-30.5%
-198.2%
Q1 24
-36.2%
-252.9%
Capex Intensity
BZFD
BZFD
DNA
DNA
Q4 25
0.5%
0.0%
Q3 25
1.8%
0.0%
Q2 25
1.0%
0.1%
Q1 25
1.1%
15.8%
Q4 24
0.3%
31.3%
Q3 24
0.5%
16.9%
Q2 24
0.3%
48.1%
Q1 24
0.2%
17.7%
Cash Conversion
BZFD
BZFD
DNA
DNA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-0.15×
Q3 24
4.59×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BZFD
BZFD

Advertising$25.6M45%
Commerce And Other$16.3M29%
Content$14.7M26%

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

Related Comparisons